STEP 1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Body composition
The compartment called lean mass contains water, glycogen, viscera and skin. Only some of it is the tissue anybody is worried about.
Almost every disagreement about muscle loss on incretin therapy turns out, on inspection, to be a disagreement about measurement rather than about physiology. One party is quoting dual-energy X-ray absorptiometry from a trial substudy; another is quoting a bioimpedance readout from a gym scale; a third is quoting the difference between two bioimpedance readouts taken at different times of day and in different states of hydration. These are not three estimates of the same quantity. They are three quantities, and the spread between them is comfortably wide enough to accommodate any conclusion a person arrives wanting.
Every widely used body-composition instrument partitions the body into compartments, and the compartment names do more work than they should. In the standard three-compartment DXA output, a body consists of fat mass, bone mineral content and lean soft tissue. The third of those is defined by subtraction: it is what remains once fat and bone are accounted for. It therefore includes skeletal muscle, cardiac and smooth muscle, the liver, kidneys, gut and other viscera, the skin, the blood, and all extracellular and intracellular water.
The water term is the one that causes the most confusion in the first weeks of treatment. Muscle glycogen binds water at roughly three grams per gram, so a shift in glycogen stores produces a change in lean mass measurement several times its own size. Reduced food intake, reduced carbohydrate intake and reduced training volume all lower glycogen. A person who reads a two-kilogram fall in lean mass across the first month of treatment may have lost very little muscle and a good deal of water, and no instrument in routine use can tell them which.
This is not a pedantic distinction. It determines whether an early reading is alarming or unremarkable, and it is the reason the Journal treats composition measurements taken inside the first eight weeks of treatment as close to uninterpretable.
There is a technique that estimates whole-body skeletal muscle mass rather than inferring it from a subtraction. Deuterated creatine dilution involves an oral dose of labelled creatine, which distributes into the total creatine pool — almost all of which sits in skeletal muscle — with the enrichment of labelled creatinine in a subsequent urine sample giving an estimate of pool size and therefore of muscle mass.1 It is not an imaging measure and it does not depend on regression equations fitted to a reference population.
Comparisons with DXA are instructive and slightly deflating. The two methods correlate only moderately in older adults, and where they disagree the creatine-dilution figure has been the better predictor of physical function and of incident disability. That is an argument that DXA appendicular lean mass, the standard proxy, is measuring something adjacent to what matters rather than the thing itself.
The method has been available for more than a decade. It has been used in no trial of any drug in this class. It requires a timed urine collection and a mass spectrometry laboratory, which is a modest imposition set against the volume of argument the absence of good muscle-mass data has generated.
The trials measured mass. Nobody measured whether the participants got weaker, and that measurement costs almost nothing.
On the missing endpointClinical teaching has long held that approximately twenty-five per cent of the mass lost during weight reduction is fat-free tissue. The figure appears in textbooks, in review articles and in a great deal of consumer material, usually without a citation and always without an interval.
A critical review published in 2014 traced the rule to a limited number of older studies, examined the variation across the wider literature, and concluded that treating one-quarter as a constant is not defensible.2 The fraction of loss that is fat-free tissue varies systematically with baseline adiposity — heavier people lose proportionally more fat — and with the rate of loss, the protein intake, the activity pattern and the measurement method. Reported values span from well under fifteen per cent to above thirty-five.
This matters for the current argument in a specific way. Both the reassuring and the alarming readings of the incretin substudy data are constructed by comparing an observed fat-free fraction against the one-quarter benchmark. If the benchmark is a loose average rather than an expectation, both comparisons are weaker than they appear, and the honest statement is that the observed fractions sit within the range that dietary weight loss has always produced.
| Target | Population it was established in | Duration | Denominator used |
|---|---|---|---|
| 0.8 g/kg/day | General adult requirement, nitrogen balance | Weeks | Current body weight |
| 1.2–1.5 g/kg/day | Older adults, energy restriction | 6–12 months | Current or adjusted weight |
| 1.6 g/kg/day | Resistance training, plateau of accrual | 8–16 weeks | Current body weight |
| 2.4 g/kg/day | Resistance-trained young men, large deficit | 4 weeks | Current body weight |
| 1.5 g/kg reference weight | Obesity management guidance | Not trial-derived | Reference or ideal weight |
| No target in this table was established in anybody taking a GLP-1 receptor agonist. The denominator column is the reason the same ratio produces targets differing by a third or more. | |||
There is a rhetorical move available to both sides of this argument and it works by choosing a denominator. Report lean mass as a proportion of total body mass and it rises during successful treatment, because fat is falling faster; the treatment looks composition-improving, which it is. Report lean mass in absolute kilograms and it falls; the treatment looks muscle-costing, which it also is. Both statements can be made from the same scan pair without either being false.
The Journal reports both, in that order, and thinks anybody presenting only one should be asked why. The proportional figure is the right one for questions about metabolic quality: a body with a higher lean fraction handles glucose better and carries less ectopic fat. The absolute figure is the right one for questions about function and reserve, because a hip fracture at seventy-eight is not prevented by a favourable ratio.
The two framings also diverge most sharply exactly where the stakes are highest. A person losing twenty-five per cent of their body weight will show an excellent proportional result and the largest absolute lean-mass reduction in the cohort. Selecting the framing selects the conclusion, which is why the trade has settled on whichever one suits it.
Densitometry infers bone mineral density from the differential attenuation of two X-ray energies, using the surrounding soft tissue as the baseline against which bone is distinguished. The algorithm assumes a soft-tissue composition, and that assumption is embedded in the calibration. When the thickness and fat fraction of the tissue overlying a measurement site change substantially, part of the apparent change in bone density is an artefact of the altered baseline.
The magnitude is contested. Phantom and cadaver work suggests errors of the order of one to three per cent for large changes in overlying fat, which is the same order as the real bone changes being reported over a year of rapid weight loss. In practice this means that a hip bone mineral density reduction of two per cent in a person who has lost a fifth of their body weight cannot be cleanly separated into a bone effect and a measurement effect, and the published analyses do not attempt it.
Quantitative computed tomography and high-resolution peripheral imaging are less vulnerable, measure geometry and microarchitecture rather than areal density, and have not been used in any trial in this class. The Journal regards that as the most easily closed gap in the whole body-composition literature.
Two things follow practically and only two. Eating adequate protein and loading the skeleton during rapid weight loss are supported by general physiology, carry negligible risk, and are worth doing. Expecting either to prevent lean-mass loss outright is not supported by anything, and treating a fall in a DXA number as a failure of adherence is a misreading of what the number can tell you.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Where the curve flattens, what flattens with it, and what does not.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A design note rather than a result: what the comparator was, and what that permits you to conclude.